MDMA-Assisted Therapy for Posttraumatic Stress Disorder: A Mixed-Methods Case Study of a Participant of Color From an Open-Label Trial
In a mixed-methods case study of a participant of colour from an open-label MDMA-assisted therapy trial, MDMA-AT produced quantitative reductions in PTSD symptoms and interpretative phenomenological analysis identified psychological mechanisms of change alongside additional positive and negative effects. The study emphasises the importance of attending to culturally relevant material in MDMA-AT and offers recommendations for culturally attuned practice.
Authors
- Rick Doblin
- Berra Yazar-Klosinski
- Amy Emerson
Published
Abstract
MDMA (±3,4-methylenedioxymethamphetamine)-assisted therapy (MDMA-AT) was shown in previous clinical trials to have promising efficacy and safety for alleviating treatment-resistant posttraumatic stress disorder (PTSD). However, due to low ethnoracial diversity, the question remains as to whether ethnoracial minority participants would benefit similarly. Thus, a mixed-methods case study was conducted on a participant of color from an open-label trial of MDMA-AT for PTSD to provide a culturally informed lens on symptom recovery with this treatment approach. An additional aim was to elucidate mechanisms of change underlying this treatment for the participant. A case profile was provided, documenting quantitative improvement in PTSD symptoms. This was followed by an interpretative phenomenological analysis (IPA) of effects and mechanisms of action for this participant, based on integration session transcripts. Results of IPA indicated recurrent themes related to psychological mechanisms of symptom change, reduced PTSD symptoms, and additional effects (positive and negative) beyond PTSD symptom reduction. These themes were discussed and recommendations for attuning to culturally relevant material during MDMA-AT were provided.
Research Summary of 'MDMA-Assisted Therapy for Posttraumatic Stress Disorder: A Mixed-Methods Case Study of a Participant of Color From an Open-Label Trial'
Introduction
MDMA-assisted therapy (MDMA-AT) has shown promising efficacy and safety for treatment-resistant posttraumatic stress disorder (PTSD) in pooled Phase II data, but prior trials have included few participants from ethnoracial minority groups. The authors note that only 12.4% of the pooled Phase II sample identified as individuals of colour, and argue this is important given higher PTSD risk among some ethnoracial groups and potential barriers to diagnosis and care related to systemic and interpersonal race-based stressors. Ching and colleagues conducted a mixed-methods single-case study of a first-generation South Asian American participant from an open-label MDMA-AT trial. The study aimed both to provide a culturally informed lens on recovery from PTSD for this participant and to elucidate immediate, ecologically valid change processes and therapeutic mechanisms of MDMA-AT by analysing integration-session transcripts in detail. The authors acknowledge limited generalisability but frame the case as a stimulus for deeper consideration of cultural diversity and mechanisms in MDMA-AT research.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Ching, T. H. W., Williams, M. T., Reed, S. J., Kisicki, M. D., Wang, J. B., Yazar-Klosinski, B., Emerson, A., & Doblin, R. (2024). MDMA-Assisted Therapy for Posttraumatic Stress Disorder: A Mixed-Methods Case Study of a Participant of Color From an Open-Label Trial. Journal of Humanistic Psychology, 64(4), 692-722. https://doi.org/10.1177/00221678221076993
Related Clinical Trials
References (15)
Papers cited by this study that are also in Blossom
Amoroso, T., Workman, M. · Journal of Psychopharmacology (2016)
Barone, W., Beck, J., Mitsunaga-Whitten, M. et al. · Journal of Psychoactive Drugs (2019)
Carhart-Harris, R. L., Erritzoe, D., Haijen, E. C. H. M. et al. · Psychopharmacology (2017)
Dolder, P. C., Müller, F., Schmid, Y. et al. · Psychopharmacology (2017)
Feduccia, A. A., Jerome, L., Yazar-Klosinski, B. et al. · Frontiers in Psychiatry (2019)
Feduccia, A. A., Mithoefer, M. C. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018)
Gorman, I., Belser, A. B., Jerome, L. et al. · Journal of Traumatic Stress (2020)
Hendricks, P. S. · International Review of Psychiatry (2018)
Jerome, L., Feduccia, A. A., Wang, J. B. et al. · Psychopharmacology (2020)
Johansen, P. Ø., Krebs, T. S. · Journal of Psychopharmacology (2009)
Show all 15 referencesShow fewer
Jungaberle, H., Thal, S., Zeuch, A. et al. · Neuropharmacology (2018)
Mithoefer, M. C., Feduccia, A. A., Jerome, L. et al. · Psychopharmacology (2019)
Richards, W. A. · Journal of Humanistic Psychology (2016)
Wagner, A. C., Mithoefer, M. C., Mithoefer, A. T. et al. · Journal of Psychoactive Drugs (2019)
Wagner, M. T., Mithoefer, M. C., Mithoefer, A. T. et al. · Journal of Psychopharmacology (2017)
Cited By (2)
Papers in Blossom that reference this study
Ching, T. H. W., Stahnke, B., Shnayder, S. et al. · Frontiers in Psychiatry (2025)
Barone, W., Mitsunaga-Whitten, M., Blaustein, L. O. et al. · Frontiers in Psychiatry (2022)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.